Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 3
1982 4
1983 1
1984 2
1985 1
1987 5
1988 1
1989 6
1990 3
1991 6
1992 2
1994 2
1995 4
1996 1
1997 3
2000 1
2001 1
2002 1
2003 1
2005 1
2006 2
2007 7
2008 1
2009 2
2010 3
2011 3
2012 8
2013 7
2014 5
2015 8
2016 9
2017 9
2018 7
2019 6
2020 5
2021 4
2022 1
2023 2
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Continuous Infusion of Hypertonic Saline vs Standard Care on 6-Month Neurological Outcomes in Patients With Traumatic Brain Injury: The COBI Randomized Clinical Trial.
Roquilly A, Moyer JD, Huet O, Lasocki S, Cohen B, Dahyot-Fizelier C, Chalard K, Seguin P, Jeantrelle C, Vermeersch V, Gaillard T, Cinotti R, Demeure Dit Latte D, Mahe PJ, Vourc'h M, Martin FP, Chopin A, Lerebourg C, Flet L, Chiffoleau A, Feuillet F, Asehnoune K; Atlanrea Study Group and the Société Française d’Anesthésie Réanimation (SFAR) Research Network. Roquilly A, et al. JAMA. 2021 May 25;325(20):2056-2066. doi: 10.1001/jama.2021.5561. JAMA. 2021. PMID: 34032829 Free PMC article. Clinical Trial.
High DOCK1 expression identifies a distinct prognostic subgroup of pediatric acute myeloid leukemia: Results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial.
Yoshitomi M, Tsujimoto SI, Ikeda J, Kawai T, Ohki K, Hara Y, Yamato G, Tanoshima R, Tomizawa D, Shimada A, Horibe K, Adachi S, Taga T, Tawa A, Hayashi Y, Ito S, Shiba N. Yoshitomi M, et al. Among authors: tawa a. Pediatr Blood Cancer. 2024 Sep;71(9):e31151. doi: 10.1002/pbc.31151. Epub 2024 Jul 2. Pediatr Blood Cancer. 2024. PMID: 38953149
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia.
Iyoda S, Yoshida K, Shoji K, Ito N, Tanaka M, Nannya Y, Yamato G, Tsujimoto S, Shiba N, Hayashi Y, Shiozawa Y, Shiraishi Y, Chiba K, Okada A, Tanaka H, Miyano S, Koga Y, Goto H, Moritake H, Terui K, Ito E, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Takita J, Nishikori M, Adachi S, Ogawa S, Matsuo H. Iyoda S, et al. Among authors: tawa a. Leukemia. 2024 Jul;38(7):1609-1612. doi: 10.1038/s41375-024-02244-4. Epub 2024 Apr 18. Leukemia. 2024. PMID: 38632314 No abstract available.
A prolonged multispecies outbreak of IMP-6 carbapenemase-producing Enterobacterales due to horizontal transmission of the IncN plasmid.
Yamagishi T, Matsui M, Sekizuka T, Ito H, Fukusumi M, Uehira T, Tsubokura M, Ogawa Y, Miyamoto A, Nakamori S, Tawa A, Yoshimura T, Yoshida H, Hirokawa H, Suzuki S, Matsui T, Shibayama K, Kuroda M, Oishi K. Yamagishi T, et al. Among authors: tawa a. Sci Rep. 2020 Mar 5;10(1):4139. doi: 10.1038/s41598-020-60659-2. Sci Rep. 2020. PMID: 32139745 Free PMC article.
A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.
Shinkoda Y, Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, Takedani H, Kawasugi K, Taki M, Matsushita T, Tawa A, Nogami K, Higasa S, Kosaka Y, Fujii T, Sakai M, Migita M, Uchiba M, Kawakami K, Sameshima K, Ohashi Y, Saito H. Shinkoda Y, et al. Among authors: tawa a. Haemophilia. 2017 Jan;23(1):59-66. doi: 10.1111/hae.13050. Epub 2016 Aug 1. Haemophilia. 2017. PMID: 27480904 Clinical Trial.
A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, Amano K, Takedani H, Tamashima S, Matsushita T, Tawa A, Tanaka I, Higasa S, Kosaka Y, Fujii T, Sakai M, Migita M, Kawakami K, Ohashi Y, Saito H. Shirahata A, et al. Among authors: tawa a. Haemophilia. 2013 Nov;19(6):853-60. doi: 10.1111/hae.12205. Epub 2013 Jun 6. Haemophilia. 2013. PMID: 23738888 Clinical Trial.
Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.
Shiba N, Yoshida K, Hara Y, Yamato G, Shiraishi Y, Matsuo H, Okuno Y, Chiba K, Tanaka H, Kaburagi T, Takeuchi M, Ohki K, Sanada M, Okubo J, Tomizawa D, Taki T, Shimada A, Sotomatsu M, Horibe K, Taga T, Adachi S, Tawa A, Miyano S, Ogawa S, Hayashi Y. Shiba N, et al. Among authors: tawa a. Blood Adv. 2019 Oct 22;3(20):3157-3169. doi: 10.1182/bloodadvances.2019000404. Blood Adv. 2019. PMID: 31648321 Free PMC article.
EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.
Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe K, Kodama K, Tokumasu M, Itoh H, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Shiba N, Ohki K, Hayashi Y, Yamashita Y, Shimada A, Tanaka S, Adachi S. Matsuo H, et al. Among authors: tawa a. Haematologica. 2014 Nov;99(11):e225-7. doi: 10.3324/haematol.2014.107128. Epub 2014 Jul 11. Haematologica. 2014. PMID: 25015941 Free PMC article. No abstract available.
128 results